Metastatic behavior of breast cancer subtypes.

By H. Kennecke, R. Yerushalmi, R. Woods, M. Cheang, D. Voduc, C. Speers, Torsten O. Nielsen, K. Gelmon. Journal of Clinical Oncology, 2010

2,071 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/7d35fc99bf5c9de099497c45df59af762acaffa6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Andrew J. Ewald
2. Zena Werb
3. H. Moses
4. Pengfei Lu
5. Valerie M. Weaver

In Oncology

1. Andrew J. Ewald
2. Zena Werb
3. H. Moses
4. Pengfei Lu
5. R. Weinberg
6. D. Hanahan
7. Raghu Kalluri
8. J. Massagué

In Pathology and Forensic Medicine

1. H. Moses

Citations in the corpus

• Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (2016, background): “5% to brain, bone and lung, respectively[28].”
• Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype (2011, background): “The described CD44 + CD24 (cid:1) /low and ALDH1+ CSC phenotypes seem to identify breast CSC with distinct levels of differentiation.”
• Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program (2013, background): “Consistent with this concept, luminal breast cancers have a more favorable average prognosis, but 8%–21% of cases eventually metastasize to liver, lung, or brain (Kennecke et al., 2010).”